About this article
Medically reviewed- Written by
- Dr Paul Watson
- Medically reviewed by
- Dr Han Simpson
- Published
- June 4, 2026
- Medical review date
- September 8, 2026
- Evidence searched through
- September 8, 2026
- Next review due
- September 8, 2027
- Intended audience
- General Readers & Patients
- Geographic scope
- Worldwide
- Conflicts of interest
- None declared.
- Funding
- Website Owner
- Report a correction
- Report an error or editorial concern
- Medical disclaimer
- Read the medical disclaimer
As retatrutide continues to generate excitement among doctors, researchers, investors, and patients, one question is increasingly appearing in search results:
Who makes retatrutide?
The answer is simple:
Retatrutide is developed and manufactured by Eli Lilly and Company, one of the largest pharmaceutical companies in the world and the same company responsible for Mounjaro (tirzepatide) and Zepbound.
However, there is much more to the story.
Retatrutide has become one of the most closely watched obesity medications ever developed because early clinical trials have demonstrated some of the largest weight loss results seen with any drug therapy to date.
In this comprehensive guide, we’ll explain who owns retatrutide, who developed it, how it works, why Eli Lilly created it, and when it may become available.
Who Makes Retatrutide?
If you’re searching for:
- Who makes retatrutide?
- Who manufactures retatrutide?
- What company makes retatrutide?
The answer is:
Eli Lilly and Company.
Eli Lilly and Company is a global pharmaceutical corporation headquartered in Indianapolis.
Founded in 1876, the company develops treatments in areas including:
- Diabetes
- Obesity
- Oncology
- Neurology
- Immunology
- Cardiovascular disease
Today, Eli Lilly is considered one of the leaders in obesity medicine thanks to its successful development of tirzepatide.
Who Owns Retatrutide?
Retatrutide is owned by Eli Lilly.
The company holds the intellectual property rights, patents, development rights, and commercialisation rights associated with the medication.
This means Eli Lilly controls:
- Clinical development
- Manufacturing
- Regulatory submissions
- Future marketing
- Global distribution
If approved, Eli Lilly would become the exclusive manufacturer of branded retatrutide products.
Who Developed Retatrutide?
Retatrutide was created by Eli Lilly’s pharmaceutical research and development division.
The medication was designed as a next-generation obesity treatment following the success of:
- Trulicity (dulaglutide)
- Mounjaro (tirzepatide)
- Zepbound (tirzepatide)
Researchers sought to improve upon existing therapies by targeting an additional metabolic pathway.
The result was retatrutide.
What Is Retatrutide?
Retatrutide is an investigational obesity medication currently undergoing Phase 3 clinical trials.
Unlike previous weight loss medications, retatrutide activates three hormone receptors simultaneously.
GLP-1 Receptors
These help:
- Reduce hunger
- Slow gastric emptying
- Improve satiety
GIP Receptors
These may help:
- Improve insulin function
- Enhance metabolic regulation
Glucagon Receptors
These may contribute to:
- Increased calorie expenditure
- Enhanced fat metabolism
Because it activates all three pathways, retatrutide is commonly described as a:
Triple agonist weight loss drug.
Why Did Eli Lilly Create Retatrutide?
Obesity affects hundreds of millions of people worldwide.
Although medications such as semaglutide and tirzepatide have produced impressive results, researchers continue searching for therapies capable of producing even greater weight loss.
Eli Lilly developed retatrutide to potentially:
- Improve weight loss outcomes
- Enhance metabolic health
- Reduce obesity-related complications
- Expand treatment options for patients
The company’s goal is to build on the success already achieved with Mounjaro and Zepbound.
Is Retatrutide Made by the Same Company as Mounjaro?
Yes.
Both medications are developed by Eli Lilly.
Mounjaro
Contains:
Targets:
- GLP-1
- GIP
Retatrutide
Targets:
- GLP-1
- GIP
- Glucagon
Retatrutide can be viewed as the next evolution of Lilly’s metabolic medicine platform.
Is Retatrutide Made by the Same Company as Ozempic?
No.
Ozempic is manufactured by Novo Nordisk.
This creates one of the biggest rivalries in modern healthcare.
Eli Lilly Portfolio
- Mounjaro
- Zepbound
- Retatrutide
Novo Nordisk Portfolio
- Ozempic
- Wegovy
- Rybelsus
These companies currently dominate the obesity treatment market.
Why Has Retatrutide Generated So Much Attention?
Interest surged after clinical trials demonstrated substantial weight loss.
In published obesity studies, participants receiving higher Retatrutide doses achieved average weight reductions approaching 24% of body weight over 48 weeks.
These results attracted attention from:
- Physicians
- Endocrinologists
- Weight loss clinics
- Investors
- Patients
As a result, search terms such as:
- Eli Lilly retatrutide
- Retatrutide manufacturer
- Who owns retatrutide
- Retatrutide stock
have increased dramatically.
Retatrutide Development Timeline
| Year | Milestone |
|---|---|
| 2021 | Early human development |
| 2022 | Clinical studies expanded |
| 2023 | Major obesity trial results published |
| 2024 | Phase 3 studies launched |
| 2025 | Global Phase 3 recruitment continued |
| 2026 | Regulatory submissions anticipated |
Is Retatrutide Approved?
At present:
- Phase 3 studies are ongoing
- Regulatory review has not been completed
- Routine prescribing is unavailable
This means retatrutide cannot currently be prescribed as a standard treatment.
When Could Retatrutide Be Available?
Many people searching “Who makes retatrutide?” also want to know when it may become available.
The answer depends on:
- Clinical trial outcomes
- Regulatory review
- Manufacturing readiness
- Safety assessments
If approved, retatrutide could eventually become available through:
- Hospitals
- Pharmacies
- Specialist weight loss clinics
- Healthcare providers
However, no official launch date has been confirmed.
What Could Retatrutide Mean for Eli Lilly?
Many analysts believe retatrutide could become one of the most commercially successful pharmaceutical products ever launched.
Potential reasons include:
- Rising obesity rates
- Strong clinical results
- Growing demand for obesity treatments
- Established physician familiarity with Lilly products
This is one reason why investors closely follow retatrutide’s development progress.
Frequently Asked Questions
Who Makes Retatrutide?
Retatrutide is developed and manufactured by Eli Lilly and Company.
Who Owns Retatrutide?
Eli Lilly owns the patents and development rights associated with retatrutide.
Is Retatrutide Made by Eli Lilly?
Yes.
Retatrutide is part of Eli Lilly’s obesity and metabolic disease portfolio.
Is Retatrutide Made by Novo Nordisk?
No.
Novo Nordisk manufactures Ozempic and Wegovy.
Is Retatrutide the Same as Mounjaro?
No.
Retatrutide and Mounjaro are different medications, although both are developed by Eli Lilly.
Is Retatrutide Approved Yet?
Retatrutide remains in clinical development and has not yet received routine regulatory approval.
Why Is Retatrutide Important?
Retatrutide is one of the first triple agonist obesity medications and has demonstrated significant weight loss potential in clinical trials.
Final Thoughts
If you’re wondering who makes retatrutide, the answer is Eli Lilly and Company.
The pharmaceutical giant behind Mounjaro, Zepbound, and Trulicity is now developing retatrutide as its next-generation obesity treatment. By targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide has become one of the most closely watched medications in development.
Although the drug is not yet approved, its progress continues to attract worldwide attention from healthcare professionals, patients, researchers, and investors alike